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Abstract
Ovarian cancer is themost lethal gynecologic cancer in women. Its highmortality rate (68%) reflects the fact that 75%
of patients have extensive (>stage III) disease at diagnosis and also the limited efficacy of currently available therapies.
Consequently, there is clearly a great need to develop improved upfront and salvage therapies for ovarian cancer.
Here, we investigated the efficacy of metformin alone and in combination with cisplatin in vivo. A2780 ovarian cancer
cells were injected intraperitoneally in nude mice; A2780-induced tumors in nude mice, when treated with metformin
in drinking water, resulted in a significant reduction of tumor growth, accompanied by inhibition of tumor cell prolif-
eration (as assessed by immunohistochemical staining of Ki-67, Cyclin D1) as well as decreased live tumor size and
mitotic cell count. Metformin-induced activation of AMPK/mTOR pathway was accompanied by decreased micro-
vessel density and vascular endothelial growth factor expression. More importantly, metformin treatment inhibited
the growth of metastatic nodules in the lung and significantly potentiated cisplatin-induced cytotoxicity resulting in
approximately 90% reduction in tumor growth compared with treatment by either of the drugs alone. Collectively,
our data show for the first time that, in addition to inhibiting tumor cell proliferation, metformin treatment inhibits
both angiogenesis and metastatic spread of ovarian cancer. Overall, our study provides a strong rationale for use of
metformin in ovarian cancer treatment.
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Introduction
Ovarian cancer is the fifth leading cause of cancer death in women
and the most lethal gynecologic malignancy [1]. Most patients pres-
ent with advanced disease, and despite surgical debulking followed by
platinum-based chemotherapy for advanced stage disease, the average
time of clinical remission is approximately 2 years and the 5-year sur-
vival rate is 45% [2]. These data clearly highlight the need to identify
new molecular targets and agents that can be used in the treatment of
women with ovarian cancer.
Metformin is an antidiabetic drug that, during the last decade, has
gained significant attention as an anticancer drug. Recently, owing
to extensive reports of its in vitro and in vivo antitumor activity,
many clinical trials have been initiated worldwide [3]. In patients with
diabetes, it has been found to inhibit gluconeogenesis in the liver by
impairing oxidative phosphorylation and leading to an imbalance of
the AMP/ATP ratio. Consequently, metformin reduces blood glucose
and insulin levels. The increased AMP levels also lead to the activation
of LKB1-AMPK pathway. In cancer cells, AMPK activation by met-
formin and other activators results in inhibition of the mTOR pathway
and modulates the expression of p21, p27, and cyclin D1, which in-
hibit proliferation. Although, initially it was believed that metformin’s
anticancer activity was through activation of AMPK-LKB1, recent
data indicate it could also be independent of AMPK activation [4].
Consistent with these reports, our previous study in ovarian cancer cells
indicated that the effect of metformin was partially dependent on
AMPK but required LKB1 [5]. Although the precise mechanism for
this phenomenon is currently not known, it is important to realize
that metformin-mediated activation of LKB1 could also result in the
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activation of other AMPK-related kinases. However, we cannot rule out
the possibility that metformin, as a drug, may also be modulating other
yet unidentified pathways.
In this study, we provide preliminary evidence that the action of
metformin in vivo is multifaceted involving known biosynthetic path-
ways such as proliferation and protein biosynthesis and novel path-
ways such as modulation of angiogenesis and metastasis.
Materials and Methods
Reagents and Antibodies
A2780 cell lines were a kind gift of Dr Tom Hamilton (Fox Chase
Cancer Center) and were grown in RPMI medium. Metformin
(RIOMET 500 mg/5 ml) used for animals was purchased from Ranbaxy
Laboratories (Princeton, NJ). Antibodies to phospho-ACC (cat. no.
3661, used at 1:100) and phospho-mTOR (cat. no. 2976, used at
1:50) were from Cell Signaling Technology (Denver, MA). Cyclin D1
(cat. no. sc753, used at 1:50) and CD31 (PECAM) (cat. no. sc31045,
used at 1:100) were from Santa Cruz Biotechnology (Santa Cruz, CA);
Ki-67 (cat. no. M7240, used at 1:100) was from Dako (Glostrup,
Denmark), and vascular endothelial growth factor (VEGF; cat. no.
ab3109, used at 1:50 for immunohistochemistry and 1:1000 for
Western blot) antibody was purchased from Abcam (Cambridge, MA).
Animals
All animal experiments were done according to an Institutional
Animal Care and Use Committee–approved protocol. Institutional
guidelines for the proper and humane use of animals in research were
followed. The facility has been approved by Association for Assess-
ment and Accreditation of Laboratory Animal Care. Female nude
mice were used between the ages of 6 and 7 weeks and purchased
from the National Cancer Institute. Before injecting into animals,
the cells were washed twice, counted, and resuspended in PBS at
2 × 106/100 μl. A2780 cells (2 × 106 suspended in 100 μl of
PBS) were inoculated into the intraperitoneal cavity of mice (day 0).
Treatment with metformin was started 7 days after inoculation of the
cells. Metformin was dissolved in 200 ml of drinking water to attain the
dosages of 100 and 200 mg/kg body weight. The water was changed
daily and measured for water intake. Metformin treatment was con-
tinued for the next 3 weeks until the mice were killed at 4 weeks.
The mice were monitored daily for any discomfort and weighed every
third day to check for tumor growth. For combination studies, cis-
platin treatment (4 mg/kg body weight) by intraperitoneal injections
was given on days 7, 14, and 21 along with metformin treatment as
described above (day 0 was taken as the day of inoculation of cells).
The main purpose of giving metformin in water was to maintain
a constant level of metformin and sustained activation of AMPK in
mouse as opposed to that achieved by a single dose, which gets
cleared rapidly from the system. In patients, metformin is now pref-
erably given in an extended release form, which can maintain the
effect of metformin for a long duration and is therefore more effec-
tive. The XR tablet cannot be administered to animals because break-
ing or grinding the tablet compromises its slow-release ability (our
experience and manufacturer’s recommendation).
A recent well-established method to translate the dose of drugs used
from one animal species to another has been published by Reagan-
Shaw et al. [6] and also found at the National Cancer Institute Web site
(http://dtp.nci.nih.gov). According to the formula, human equivalent
dose (mg/kg) = animal dose (mg/kg) × animal Km/human Km, where
species and Km values are based on body surface area (Km for adult
human [60 kg] is 37 and mouse [20 g] is 3). On the basis of this for-
mula, the human equivalent dose of 100mg inmouse is 480mg/average
size person of 60 kg, which is five times lower than the maximum safe
dose of 2550 mg/d recommended in the Physician’s Desk Reference.
Cytotoxicity Assays
Blood was collected in heparin-coated tubes just before mice were
killed. Plasma isolated from blood of 6 mice from each group was sub-
jected to analysis of a panel of hepatic function tests (aspartate amino-
transferase [AST], alanine aminotransferase [ALT], albumin), kidney
function tests (creatinine, urea, albumin), and glucose. All assays were
performed using kits from Bioassay Systems (Hayward, CA). All assays
were performed according to the manufacturer’s instructions.
Immunohistochemistry
The tumors excised from mice were fixed in 10% paraformalde-
hyde for 48 hours and paraffin-embedded. Four-micrometer-thick
consecutive sections were cut and processed for immunohistochemis-
try for pACC (cat. no. 3661, used at 1:100), cyclin D1 (cat. no. sc753,
used at 1:50), pmTOR (cat. no. 2976, used at 1:50), VEGF (cat. no.
ab3109, used at 1:50), CD31 (cat. no. sc31045, used at 1:100), and
Ki-67 (cat. no. M7240, used at 1:100). Solutions obtained from Dako
Cytomation were used for performing immunostaining. In brief, tissue
sections were deparaffinized, unmasked, blocked with avidin-biotin,
and incubated with primary antibody overnight. Next day, the reaction
was detected by using chromogen according to the manufacturer’s in-
struction (Dako). The positive cells stained brown. The slides were
examined under a light microscope, and representative pictograms
were taken from a minimum of five or six different slides of each
group. For CD31 staining, fluorescein isothiocyanate–labeled second-
ary antibody was used and visualized using fluorescent microscope in
six sections per group.
Mitotic Count
The mitotic count was recorded on hematoxylin and eosin (H&E)–
stained sections using the Olympus BX-41 light microscope (Center
Valley, PA) at high-power field (HPF; ×400). Cells undergoing mitosis
were counted in the tumors, in the most active area (“hot spots”) in a
minimum of five consecutive HPFs. The average number of cells un-
dergoing mitosis per HPF was enumerated.
Live Tumor Measurements
The maximum diameter of viable tumor was calculated by sum-
ming the largest unidimensional diameter of each fragment of tumor
using the Olympus BX-41 microscope and a micrometer. Similarly,
necrotic areas were measured, and the composite live tumor size was
calculated from each slide.
Western Blot
A small part of excised xenografts from four mice of each group was
washed with PBS and immediately placed in 500 μl of protein lysis
buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA,
50 mM NaF, and 0.5% Nonidet P-40; containing a protease inhibitor
cocktail [Sigma, St Louis, MO]). The tissue was homogenized, kept on
ice for 30 minutes, and centrifuged at 10,000g for 10 minutes. Super-
natant was separated, and protein concentration was estimated by the
Bradford method (BioRad, Hercules, CA). Immunoblot analysis with
VEGF antibody (1:100) was performed as previously described [5].
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Statistical Analysis
Data were statistically analyzed using two-tailed Student t-test
(Prism, La Jolla, CA) or the Student-Newman-Keuls test (GraphPad
Software, La Jolla, CA). All animal experiments were performed at
least twice with the minimum number of animals per group being six.
Results
Metformin Inhibits Ovarian Tumor Growth In Vivo
To determine whether metformin could curtail tumor growth in vivo,
we injected A2780 cells intraperitoneally (IP) in nude mice (n = 11).
On day 7, metformin (100 and 200 mg/kg body weight) was intro-
duced in water as described in the Materials and Methods section.
Addition of metformin to water did not affect water intake by mice
(data not shown). At the end of 4 weeks, mice were killed and tumors
were excised. Figure 1A (top panel ) shows a representative photograph
of the vivisected mouse showing tumors from different groups. Con-
sistent with our previous in vitro report that metformin treatment of
ovarian cancer cells leads to reduced proliferation, A2780 xenografts
treated with metformin at two different concentrations had much
reduced tumor burden compared with untreated mice (Figure 1A,
top and middle panels). As previously reported by Shaw et al. [7], IP
injected A2780 cells formed mainly solid tumors and presented with
ovary-specificmetastases (Figure 1A, bottom panel ). The ovary-associated
tumor mass in the metformin-treated mice was significantly smaller
than that in the untreated mice. Themean weights of the excised tumors
were approximately 50% and 60% less in mice treated with metformin
Figure 1. Metformin inhibits ovarian tumor growth in vivo. (A) Gross morphology of representative vivisected mouse showing A2780
tumors (top panel), excised tumor (middle panel), and tumors associated with ovary (lower panel) at 4 weeks from each group (n = 11).
(B) Graph showing the excised tumor weight from each of each group (n = 11) with cumulative mean; untreated, Met 100 (metformin
100 mg/kg body weight), Met 200 (metformin 200 mg/kg body weight). ***P < .001, treated compared with the untreated group.
(C) Cumulative abdominal circumference from untreated, metformin 100 mg/kg body weight (Met 100) and metformin 200 mg/kg body
weight (Met 200) (n= 11) at 4 weeks. ***P< .001, treated compared with the untreated group. (D) Representative photomicrographs of
H&E (×200)–stained ovarian cancer xenografts from each group.
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100 (3.06 ± 0.06 g) and 200 mg/kg body weight (2.86 ± 0.52 g), re-
spectively, compared with untreated mice (6.72 ± 0.52 g; Figure 1B).
Also, the abdominal circumference, which is indicative of the tumor
burden being carried in the peritoneum, was significantly less in the
treated mice compared with untreated mice (Figure 1C). Representative
portions of the excised tumors were paraffin-fixed and processed for
histologic examination. On review of the H&E–stained slides, the
morphology of the excised masses (Figure 1D) was consistent with that
of epithelial ovarian carcinoma.
Although metformin has a strong safety record in human con-
sumption, we determined whether metformin treatment results in
any cytotoxicity when given to mice with ovarian tumors. Plasma
isolated from blood of six mice from the untreated group and from
those treated with 200 mg/kg was subjected to analysis of a panel of
hepatic function (AST, ALT, and albumin) and kidney function tests
(creatinine, urea [serum urea nitrogen], albumin). There was no sig-
nificant difference between the untreated and metformin-treated
mice, and all values were well within the normal limits (Figure W1).
We also determined the glucose levels because metformin is known
to lower glucose levels in patients with diabetes. There was no sig-
nificant difference between the glucose levels of untreated and
metformin-treated mice, indicating that metformin does not affect
the glucose levels in nondiabetic conditions (Figure W1).
These data thus reflect the efficacy of metformin in inhibiting the
growth of human ovarian cancer cells in vivo.
Metformin Inhibits Proliferation of Ovarian Tumors In Vivo
To investigate if metformin acts by inhibiting proliferation as pre-
viously reported by us and others in vitro, we performed immuno-
histochemistry for Ki-67. Ki-67 staining did not show any significant
difference in the intensity of the staining between treated and un-
treated mice (Figure W2A; ×100). To obtain a more clear picture,
we performed a count of Ki-67–positive cells in five HPFs in each of
three different tumors from treated and untreated mice (Figure 2A).
The counts were expressed as percentage of positive cells per field.
Although, metformin at the 100-mg/kg treatment did not show a sig-
nificant difference, xenografts treated with metformin 200 mg/kg
showed significantly less Ki-67–positive cells, indicating that less per-
centage of cells were proliferating under metformin treatment. This
maybe attributed to our previously shown observation that metformin
treatment in vitro results in G1 cell cycle arrest [5], which may also
affect the Ki-67 index because Ki-67 indicates that the cell has entered
the cell cycle but does not provide the information if the cells passes
through G1/S or G2/M phases. To further assess the viability of the
tumor, necrotic and viable tumor size was determined from H&E–
stained sections (Figure W2B, circled regions for necrotic areas of the
tumor; ×20). The ratio of live tumor size to total tumor size was cal-
culated based on the largest unidimensional diameter as described in
Materials and Methods. As shown in Figure 2B, xenografts derived
from metformin-treated mice had significantly less viable tumor sizes
and more necrotic regions compared with xenografts derived from un-
treated mice. Consistent with this observation, mitotic count measured
as described in the Materials and Methods section was higher in the
xenografts derived from untreated mice compared with mice treated
with metformin (Figure 2C). Collectively, these data demonstrate that
metformin treatment inhibits proliferation in vivo resulting in reduced
tumor size consistent with the in vitro studies.
Metformin Inhibits Metastasis and Angiogenesis in Ovarian
Tumors In Vivo
To determine whether metformin treatment had any effect on me-
tastasis, we did H&E staining of various organs. Although tumor was
visible on liver, spleen, and kidney in untreated mice, we did not see
any invasion of these tumors into these organs (data not shown).
However, significant pulmonary metastasis was seen in the lungs of
untreated mice but not in metformin-treated mice (Figure 3A). Enu-
meration of the number of metastatic nodules in the lung sections of
five different mice from each group also revealed presence of sig-
nificantly less nodules in treated versus untreated mice (Figure 3Di).
In addition, because new blood vessel formation is a requirement
for tumors to grow and metastasize, we evaluated the microvascula-
ture density in the xenografts. Anti-CD31 staining showed reduced
microvessel density in metformin-treated tumors (Figure 3B, ×200)
compared with untreated mice, indicative of inhibition of angio-
genesis. Furthermore, quantification of positively stained vessels done
in five HPFs (×400) of three sections each also confirmed reduced
angiogenesis (Figure 3Dii). In addition to the reduced microvessel
density, there was significantly less staining and expression of VEGF
(Figure 3C , ×200; Figure 3Dii) in xenografts of metformin-treated
mice compared with untreated mice, further substantiating inhibition
Figure 2. Metformin inhibits proliferation of ovarian tumors in vivo. (A) Count of positive Ki-67–stained cells from five HPFs in each of
three different tumors from each group (×400) expressed as percentage. (B) Measurement of viable tumor size as described in Materials
and Methods. (C) Mitotic counts per HPF (×400) counted from five fields of three different tumors from each group. **P< .05, *P< .01,
treated groups compared with untreated.
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of angiogenesis in metformin-treated mice. Collectively, these data sug-
gest the potential of metformin in attenuating metastasis and angiogene-
sis, two essential processes required for tumor growth and sustenance.
Metformin Induces AMPK in Ovarian Tumors In Vivo
The main mechanism of action of metformin is activation of AMPK
and modulation of its downstream effectors. To assess if metformin
treatment results in activation of AMPK, we stained the tumor sections
for pACC, the direct downstream target of AMPK. The tumors showed
some basal expression of pACC, which was significantly increased in a
dose-dependent manner (100 and 200 mg/kg body weight) with met-
formin treatment (Figure 4A; ×200). This was also confirmed by scor-
ing of percentage positive cells per five HPF (400×) from five different
sections from each animal group (Figure 4D, first panel ). This suggests
Figure 3. Metformin inhibits metastasis and angiogenesis in ovarian tumors in vivo. (A) Representative photomicrographs of H&E
(×100)–stained lung tissues exhibiting metastasized ovarian cancer from each group. The metastatic nodules are pointed out with
arrows. Lung sections from five different mice were examined. (B) Representative staining of CD31 of blood microvessels (×200) of
A2780 xenografts in mice at 4 weeks. (C) Representative staining of VEGF (×400) in A2780 xenografts in mice at 4 weeks performed in
five sections from each group. (D) Di: Enumeration of average number of pulmonary metastatic nodules from five H&E–stained lung
sections. Dii: Count of average microvessels per HPF (×400) from five fields of three different tumor sections. Diii: Expression of VEGF
was determined by Western blot from protein of tumor tissue of four individual mice per group. Graph represents the densitometric
average of each group. ***P < .001, **P < .05, *P < .01, treated groups compared with the untreated group.
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that metformin is taken up by the tumors when given orally. To fur-
ther confirm that AMPK activation also leads to activation/inhibition
of its downstream targets, we stained for markers, which we have pre-
viously shown in vitro to be modulated by metformin [5]. Metformin
treatment was able to inhibit the expression of p-mTOR (Figure 4B;
×200) and cyclin D1 (Figure 4C ; ×400). This was also confirmed by
the scoring of percentage positive cells per five HPF (400×) from five
different sections from each animal group (Figure 4D, second and third
panels). These data strongly suggest that metformin treatment results
in AMPK activation in tumor tissues and modulates cell cycle and pro-
tein synthesis to restrain tumor growth. Our repeated attempts using
individual mouse tumors (n = 6) to determine the expression of the
same protein markers by immunoblot analysis gave inconsistent results
(data not shown). This may be due to several reasons such as tumor
heterogeneity and/or the areas of the tumors used for protein extrac-
tion. This is particularly important because we used small amounts
of tissue for lysate preparation without the knowledge of whether the
tissues used contained regions of necrosis.
Metformin Potentiates Cisplatin-Induced Cytotoxicity in
Inhibiting Tumor Growth
Metformin and/or cisplatin treatment of A2780 and its cisplatin-
resistant isogenic C200 cells in vitro significantly inhibited colony-
forming abilities and resulted in reduced colony formation (Figure W3).
Therefore, after the generation of A2780 xenografts, the mice were
treated with two different doses of metformin (100 and 200 mg/kg
body weight). Weekly IP injections of cisplatin on days 7, 14, and 21
along with continuous metformin therapy were very effective in inhibit-
ing the tumor growth. The combination of cisplatin (4 mg) with met-
formin 100 mg/kg body weight (2.08 ± 0.18 g; Figure 5A) significantly
reduced tumor growth compared with metformin 100 mg/kg body
weight (3.54 ± 0.35 g) or cisplatin treatment alone (3.15 ± 0.34 g) or
Figure 4.Metformin induces AMPK in ovarian tumors in vivo and its downstream effectors. Representative staining of pACC (A, ×200),
p-mTOR (B, ×200, and cyclin D1 (C, ×400) seen in tumor sections from each group. Five slides from each group were stained. (D)
Graphical representation of percentage of positive cells counted from five HPFs (400×) per section of five different slides from each
animal group. M100 indicates metformin 100 mg/kg; M200, metformin 200 mg/kg; Unt, untreated. ***P < .001, **P < .05, *P < .01,
treated groups compared with the untreated group.
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Figure 5. Metformin and cisplatin effectively combine to inhibit ovarian tumor growth. (A) Cumulative excised tumor weight from individual
mice bearing A2780 xenografts at 4 weeks (n = 6) with metformin 100 and 200 mg/kg body weight in combination with cisplatin (4 mg).
***P < .001, **P < .05, *P < .01, metformin and cisplatin combination–treated groups compared with single-drug–treated group. (B) Bi:
Graphical representation of viable tumor size measured from four different tumors as described before. *P < .01, combination compared
with metformin and cisplatin treatment alone. Bii: Positive Ki-67 cells measured from four different tumors as described before and is rep-
resented as percentage of control. ***P < .001, **P < .05, *P < .01, treated groups compared with the untreated group. (C) Ci: Mitotic
counts per HPF from six fields of three different tumors from each group. *P < .01, treated groups compared with the untreated group. Cii:
Vessel counts per HPF (×400) from six HPFs of three tumors from each group. ***P< .001, **P< .05, treated groups compared with the un-
treated group. (D) Representative (×200) staining showing pACC indicating AMPK activation in tumor tissues excised from mice at 4 weeks.
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untreated mice (6.9 ± 0.66 g). The effect of cisplatin and metformin at
200 mg/kg body weight (0.84 ± 0.39 g) was even more pronounced
compared with metformin 200 mg/kg body weight alone (2.65 ±
0.23 g; Figure 5A). Tumor volume was reduced by ∼90% in most of
the mice, whereas three of six mice had no visible tumors. A represen-
tation of the H&E micrographs is shown in Figure W4.
Measurement of live tumor size was also further reduced in met-
formin and cisplatin combination treatments (Figure 5Bi), along
with significantly less Ki-67 index (Figure 5Bii). Similarly, mitotic
activity was less in cases of metformin and cisplatin–treated mice
when compared with cisplatin-alone–treated mice (Figure 5Ci). In-
terestingly, the most significant differences were seen in the micro-
vessel count as ascertained by CD31 staining of the xenografted
sections, where the combination of metformin and cisplatin–treated
mice had significantly less vascular density than either metformin or
cisplatin alone (Figure 5Cii). Cisplatin treatment on its own strongly
induced AMPK activity as seen by pACC staining (Figure 5D) and
was further enhanced with metformin combinations, indicating that
cisplatin can also activate the AMPK pathway. Collectively, these re-
sults suggest that combining metformin with cisplatin treatment is
very effective, leading to decreased tumor size and also angiogenesis.
Discussion
This is the first report demonstrating the in vivo potential of metfor-
min and its enhanced effectiveness with cisplatin in ovarian cancer in
reducing tumor burden, angiogenesis, and metastatic potential. In
this study, we demonstrate that metformin treatment of IP-induced
A2780 xenografts resulted in (1) reduced tumor size in nude mice,
(2) less metastatic nodules in lungs compared with untreated mice,
(3) decreased proliferation as determined by low Ki-67 index and
mitotic count and decreased cyclin D1 expression, (4) diminished
angiogenesis as determined by VEGF inhibition and from vascular
density on CD31 staining, (5) increased activity of AMPK as ob-
served by pACC levels and decreased pmTOR expression, and (6)
potentiated cisplatin-induced cytotoxicity compared with either agent
alone. Overall, our data strongly support metformin as an anticancer
agent for ovarian cancer and suggest that combining metformin with
cisplatin can increase the efficacy of cisplatin-induced cytotoxicity.
Several in vivo–based studies have demonstrated that metformin
can effectively inhibit growth of colon, pancreatic, mammary ade-
nocarcinomas, and lung carcinoma cells in AMPK-dependent and
-independent mechanisms [4]. Schneider et al. [8] showed that
metformin treatment in vivo resulted in the inhibition of pancreatic
cancer in hamsters fed a high-fat diet. Similarly, other studies have
shown that metformin specially inhibits the growth of tumors in-
duced on a high-fat diet [9]. Studies in breast cancer showed that
metformin treatment significantly decreased the tumor burden and
accumulation of mammary adenocarcinomas accompanied by in-
crease in the life span of HER-2/neu transgenic mice [10]. In these
initial reports, the authors speculated that the in vivo effects of met-
formin might be due to reducing insulin levels and mimicking a cal-
orie restriction state. Additional reports directly implicated activation
of AMPK by metformin. Metformin also reduced the size of intesti-
nal polyps while not affecting the number in ApcMin/+ mice, which
was attributed to AMPK-mediated inhibition of mTOR-S6K protein
synthesis pathway [11]. In prostate cancers, metformin treatment re-
sulted in decreased proliferation by cyclin D1 [12].
Consistent with the aforementioned studies, we have shown that
metformin is effective in inhibiting in vivo tumor burden of ovarian
xenografts, alone and in combination with cisplatin. We have also
analyzed the biomarkers of these phenotypic effects, that is, activa-
tion of AMPK (by pACC) and inhibition in activation of mTOR and
cyclin D1 expression. One of our novel observations is that we show
for the first time that metformin treatment alone resulted in de-
creased blood microvessel density (CD31 staining) and reduced
VEGF levels in the ovarian cancer xenografts, implicating an im-
portant and previously unidentified effect of metformin in inhibiting
angiogenesis in vivo. This is in contrast to studies that have shown
that AMPK activation by various means induces VEGF expression
and or angiogenesis [13–15]. AMPK activation in DU145 cells under
glucose deprivation resulted in increased levels of VEGF mRNA
stability via the JNK-ROS pathway, independent of HIF-1 and/or
LKB1 activation. Metformin-induced inhibition of angiogenic pheno-
type in our study is in contrast to the above-mentioned reports. This
could be attributed to differences in the experimental conditions such
as the in vivo setting in our study and the absence of external nutri-
tional stress to activate AMPK. In addition, in the in vitro–based stud-
ies cited above, activation of AMPK was likely transient rather than
sustained as in our in vivo studies due to continuous uptake of met-
formin in drinking water. In other non–cancer-related studies, HMEC
cells exposed to serum from polycystic ovarian syndrome patients on
metformin treatment resulted in decreased migration and invasion of
these cells through inhibition of nuclear factor-κB, Erk1/2, and Erk 5,
resulting in increased thrombospondin-1 expression, an antiangiogenic
adipokine [16]. Phosphorylation of LKB1 at S307 (a site that is also
phosphorylated after metformin treatment) leads to activation of
AMPK and results in attenuation of angiogenesis. This suggests a link
between activation of LKB1-AMPK pathway by metformin and di-
minished angiogenesis. Inhibition of inflammatory angiogenesis in a
murine sponge model by metformin provides additional supporting
data on the effect of metformin on endothelial cells [17]. Although
the precise mechanism by which metformin attenuates angiogenic
phenotype is currently not known, we do not rule out the possibility
that this phenomenon may be complex, involving other pathways that
are not regulated by AMPK, and may also be cell type dependent.
Another novel observation that we report is the inhibition of
metastasis by metformin as demonstrated by significantly fewer
and smaller metastatic nodules in the lungs of treated mice compared
with control mice. Because activation of mTOR-S6K pathway is
associated with the epithelial-mesenchymal transition phenotype,
attenuation of metastasis seen in our study could be due to the in-
hibition of mTOR pathway by metformin. Additional studies are
underway to determine the mechanistic basis of this novel obser-
vation. Whereas metformin has been shown to inhibit in vitro mi-
gration and invasion of human fibrosarcoma cells, metformin did
not inhibit lung metastasis in an in vivo metastatic breast cancer
model [18,19].
Very few reports are available citing effects of metformin and cis-
platin combination. Whereas Gotlieb et al. [20] reported metformin to
enhance cisplatin cytotoxicity in ovarian cancer cells in vitro, Harhaji-
Trajkovic et al. [21] reported metformin to protect cells from cisplatin
by inducing autophagy in glioma cells . Our data show a significant
inhibition of ovarian cancer growth when both agents are given in vitro
and in vivo. On the basis of the inhibition seen in colony forma-
tion assay with platinum-resistant C200 subline of A2780, we can
speculate that metformin will also be able to limit the growth of
platinum-resistant ovarian tumors. Additional experiments with more
platinum-resistant ovarian cancer cell lines in vitro and in vivo will
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help to answer this better. Cisplatin treatment also resulted in activa-
tion of AMPK as reported earlier [21]. Whether the enhanced anti-
tumor effect of the combination is due to activation of AMPK by
cisplatin or by augmentation of cytotoxicity by metformin remains
to be determined.
What is currently unknown is whether metformin’s antitumor ef-
fect is due to the direct effect on the growing tumor or due to its
potential to alter host physiology or a combination of both of these
effects. In our study, we found that metformin treatment increases
AMPK activation in both the tumor tissue and also potently in the
liver (Figure W5). Moreover, metformin has systemic, organism-wide
effects by reducing glucose levels, reducing insulin and IGF signal-
ing. We postulate that that the anticancer effect of metformin occurs
both at the cellular and at the organismal levels simultaneously. The
changes that occur in the tumor tissue are mainly at the cellular level
leading to changes in the signaling events (cyclin D1, p21, mTOR).
Concomitantly, there is modulation of the host AMPK activity, which
redirects the host physiology (insulin, IGF, gluconeogenesis, lipid path-
ways, leptin, adiponectin) and mimics a state of caloric restriction. All
of these host changes have been shown in preclinical studies to be
associated with a better outcome in patients with cancer. Additional
in vivo studies are needed to dissect these effects of metformin to gain
a better understanding of its mechanism of action.
Along with the large number in vitro and in vivo studies detailing
metformin’s anticancer activities and the recent reports of its ability
to target stem cells [22], there are also mounting retrospective data
from population-based studies, mainly from diabetic populations,
supporting its ability to reduce cancer risk and better outcome of dif-
ferent cancers [4]. On the basis of these studies, metformin is now
being used in various clinical trails including in a neoadjuvant setting
and in combination with other drugs [3].
Collectively, our data support the use of metformin as an antican-
cer drug alone or in combination with standard chemotherapeutic
agents that suppress proliferation, protein synthesis, angiogenesis,
and metastasis. Therefore, it provides a strong rationale for using
metformin as a therapeutic drug in combination with cisplatin in
the treatment of patients with ovarian cancer.
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Figure W1. Cytotoxic profile in plasma from A2780 tumor-bearing mice with or without metformin treatment. Before sacrificing the mice
at 4 weeks, blood was collected in heparin-coated tubes, and plasma was separated. Mouse plasma from untreated group (U) and
metformin 200 mg/kg (M) were subjected to a panel of cytotoxic tests according to the manufacturer’s instructions: (A) ALT,
(B) AST, (C) albumin, (D) BUN (serum urea nitrogen), (E) creatinine, and (F) glucose.
Figure W2. (A) Representative Ki-67 staining (×200) of excised A2780 tumors at 4 weeks. (B) Necrotic/dead areas were excluded, and
viable tumor was measured and divided by the total tumor dimension from three H&E sections (×20). Representative pictures (×20)
show encircled necrotic area excluded from viable tumor measurements.
Figure W3.Metformin inhibits colony formation in A2780 and C200
cells. A total of 2000 cells/well (A2780, C200) in six-well plates were
treated with indicated concentrations of cisplatin once. Metformin
treatments were done every third day for 2 to 3 weeks until colonies
were formed. The colonies were stained with MTT and counted.
Data represent three separate experiments done in triplicates.
***P < .001, compared with untreated cells.
Figure W4. Representative H&E (×200) staining showing morphology of A2780 ovarian tumors in mice at 4 weeks.
Figure W5. Representative (×200) staining showing pACC indicating AMPK activation in liver tissues excised from mice at 4 weeks.
